Skip to main content
. Author manuscript; available in PMC: 2012 Sep 1.
Published in final edited form as: Pediatr Blood Cancer. 2011 Jun 16;57(3):398–405. doi: 10.1002/pbc.22966

Figure 1.

Figure 1

Treatment schema for CCG-2961 and schedule of interleukin-2 (IL-2) infusions (inset) and sampling for serum IL-2 receptor (block arrows). IdaCTER is idarubicin, cytarabine, thioguanaine, etoposide, and rubidomycin (daunorubicin), HidAC is High dose Ara-C, L-asp is L-asparaginase and R is randomization.